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Abstract: Antiretroviral therapy (ART) for those infected
with HIV can prevent onward transmission of infection,
but biological efficacy alone is not enough to guide policy
decisions about the role of ART in reducing HIV incidence.
Epidemiology, economics, demography, statistics, biolo-
gy, and mathematical modelling will be central in framing
key decisions in the optimal use of ART. PLoS Medicine,
with the HIV Modelling Consortium, has commissioned a
set of articles that examine different aspects of HIV
treatment as prevention with a forward-looking research
agenda. Interlocking themes across these articles are
discussed in this introduction. We hope that this article,
and others in the collection, will provide a foundation
upon which greater collaborations between disciplines
will be formed, and will afford deeper insights into the key
factors involved, to help strengthen the support for
evidence-based decision-making in HIV prevention.
Introduction
The 19th International AIDS Conference will meet in
Washington, District of Columbia, 22–27 July 2012. Since the
last International AIDS Conference in Vienna two years ago,
more than five million people globally have become newly infected
with HIV [1,2]. In South Africa, a country with one of the largest
HIV epidemics, 3% of the young men and women who were 19
years old and uninfected at the time of the last conference will now
be infected [3]. Indications that the rate of new HIV infections in
several countries may have declined recently are extremely
welcome. Moreover, the recent UNAIDS Investment Framework
[4] and President’s Emergency Plan for AIDS Relief guidance on
combination prevention [5] suggest that combining existing
interventions and scaling them up could have further significant
impact on reducing HIV incidence. However, these strategies are
not expected to bring the epidemic fully under control.
Advances in HIV prevention research over the past two years
have generated considerable optimism. First, it was shown that a
1% tenofovir vaginal microbicide gel reduced HIV acquisition in
women in South Africa [6], and this was followed by a trial
demonstrating that daily oral co-formulated tenofovir and
emtricitabine reduced the risk of HIV acquisition in men who
have sex with men (MSM) [7]. Subsequently, daily oral tenofovir
alone or combined with emtricitabine was shown to reduce the risk
of HIV acquisition in heterosexual men and women in long-term
relationships in Uganda and Kenya [8]. There have also been
some indications that a vaccine candidate (RV144) provides some
short-term protection against infection [9]. These modalities
provide a partial reduction in risk, but some studies on pre-
exposure prophylaxis have produced conflicting results, highlight-
ing that many questions in this field remain unanswered [10].
However, the finding that has created that greatest excite-
ment has been that HIV-infected individuals who are given
antiretroviral therapy (ART) are much less likely to transmit the
infection to their heterosexual partners than those who are not.
This finding was shown in the HPTN 052 trial [11] (Box 1), which
was chosen as the Science magazine breakthrough of the year for
2011 [12]. If viral load is fully suppressed, those on ART may
effectively be almost uninfectious. Although anticipated [13,14],
this finding has catalyzed enormous interest in how ART could
not only benefit the individual provided with the medicines, but
also reduce the epidemic burden of the communities in which they
live by limiting HIV transmission.
The role of ART in reducing HIV incidence will probably be
among the most important topics in the field of HIV prevention
for years to come, and it is already being debated urgently at
national and international levels, within major normative agencies
and charities, and by donors and implementers. The issues cut
across the domains of epidemiology, economics, statistics, demog-
raphy, virology and immunology, behavioural science, mathemat-
ical modelling, and clinical trials, and demand an interdisciplinary
approach.
The HIV Modelling Consortium aims to coordinate and
promote research across these disciplines and streamline commu-
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nication between decision-makers and researchers. Mathematical
modellers have considered the potential impact of ART on HIV
incidence in a variety of scenarios and settings over the past 15 years,
with model estimates becoming more refined as improved data have
become available. A collaborative meeting of the HIV Modelling
Consortiumwas held in November 2011 (http://www.hivmodelling.
org/events/potential-impact-treatment-hiv-incidence) to review
findings and identify priorities for future research. Several
interlocking themes arose at the meeting, which are covered by
the set of articles in this special collection, ‘‘Investigating the Impact
of Treatment on New HIV Infections’’ (http://www.ploscollections.
org/TasP2012) [15–23]. In this article we seek to set each piece in
context, and describe important issues that are beyond the scope of
this collection.
The Potential Impact of ART on HIV Incidence
Fundamentally, the impact that a treatment programme can
have on preventing infections in an epidemic is determined by two
main factors. First, it is determined by the number of onward
transmissions generated by a newly infected person before they start
treatment, which is determined by the biology of HIV infection,
patterns of sexual contact between partners, the effects of other
prevention interventions, and the rates of HIV testing and linking
to care (Figure 1). Second, the impact is determined by the
number of onward infections generated by an individual after ART
initiation, which additionally depends on the biological efficacy of
treatment, as well as adherence and retention in care. Estimating
the population-level impact of expanded access to ART therefore
involves synthesising diverse sources of information and managing
substantial amounts of uncertainty about virology, immunology,
human sexual behaviour, and the long-term performance of
prevention programmes. The biological efficacy data provided by
the HPTN 052 trial [11] is only one piece of this puzzle.
Mathematical models provide a framework within which to
assemble this information, and several models of the epicentre of
the worldwide epidemic, sub-Saharan Africa, have been developed
and used to investigate the potential impact of treatment on HIV
incidence. As different studies have addressed different questions
and made different assumptions, it has been unclear whether or
not these models fundamentally agree about the potential impact
of particular treatment interventions in reducing HIV incidence. If
they do, this could increase confidence in their collective findings,
but if they do not, then this provides an important note of caution
when considering results and highlights areas for further investi-
gation.
A Systematic Comparison of 12 Models
In this collection, Eaton et al. [15] present the results of a
systematic model comparison exercise in which 12 of these models
were used to simulate the same sets of interventions. The model
results were relatively consistent for short-term (eight-year)
projections of reductions in incidence associated with treatment.
For instance, if, hypothetically, 80% of individuals were treated
after their CD4 cell count reaches 350 cells/ml (approximating
current international guidelines; Box 2), the models projected that
the incidence rate would be reduced by 35%–54% after eight
years, compared with what the incidence would be in the absence
of any ART. All models suggested that the existing treatment
scale-up in South Africa should have already reduced new
infections (incidence in 2011 is estimated to be 17%–32% lower
than if there had been no ART [15]). The consensus that
treatment provided within current guidelines has a prevention
benefit is significant and should serve to reinforce the case for
continuing to improve access to ART. However, there was much
more variation in long-term (38-year) projections of reductions in
incidence. One important way in which the models differ is in how
they represent the behaviours leading to transmission, such as
heterogeneity in sexual risk behaviours and patterns of contact
with respect to age, which are notoriously hard to quantify [24].
Another difference is in how they represent the biology of
infection, in particular the rate of CD4 cell count decline and
relative infectiousness [25,26], about which there is little compre-
hensive agreement. It will be important to consider the influence of
these factors on the key outcomes of interest when interpreting
future modelling studies on this topic.
Connecting Model Projections to the ‘‘Real World’’
When using extremely ambitious assumptions about the ability
of ART programmes to test and start treatment of HIV-infected
individuals very soon after infection, and retain them in care, five
of nine models compared by Eaton et al. [15] suggested that
incidence would be reduced by more than 90%, similar to the
modelling predictions reported by Granich et al. [27]. However,
these assumptions can be contrasted with recent real world
experience in which the HIV testing rate was 52% in the cross-
sectional, nationally representative South African National HIV
Prevalence, Incidence, Behaviour and Communication Survey [3],
and the repeat testing rate of individuals in an intensive
community-mobilising intervention was 28% [28]. In addition,
linkage from testing to ART uptake is assumed to be 100% in the
Box 1. The HPTN 052 Trial
The HPTN 052 trial enrolled 1,763 HIV-1 serodiscordant
couples (i.e., couples in which one partner is HIV-infected
but the other is not) in which the CD4 cell count for the
HIV-infected partner was between 350 and 550 cells/ml.
The HIV-infected partners were randomized either to
receive ART immediately (‘‘early ART’’ arm) or to receive
ART when their CD4 cell count dropped below 250 cells/ml
(‘‘delayed ART’’ arm). The couples were followed up for a
median of 1.7 years, and substantial effort was made to
ensure that viral suppression was achieved among those in
the early ART arm. A total of 39 transmission events were
observed. Genetic linkage analysis confirmed that 28 of
these were linked to the stable partner. Of these 28 linked
transmissions, 27 were in the delayed ART arm and one
was in the early ART arm, resulting in an estimated 96%
reduction (95% confidence interval: 73%–99%) in the risk
of transmission from HIV-infected individuals on early ART
compared with delayed ART. Earlier ART was also
associated with significant improvement in a composite
indicator of morbidity and mortality (41% [95% confidence
interval: 12%–60%] reduction).
Although the HPTN 052 study was the first randomized
controlled study to demonstrate the impact of ART on
transmission, an earlier observational study among cou-
ples recruited for another trial had previously indicated
that ART was associated with a 92% reduction in the risk of
transmission [13]. Other observational studies also support
that the risk of transmission when virally suppressed on
ART is very substantially reduced [14,57]. However, many
questions remain about the impact of ART on transmis-
sion, including the durability of the effect, levels of
suppression that would be possible in other settings,
and the impact through other routes of HIV transmission
(especially unprotected anal sex).
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models, but has been about 33% in actual programmes [29].
Rather than 0% refusal of uptake of treatment, as assumed in the
models, some settings have seen 20% refusal [30]. Finally, the
dropout rate from programmes was 1.7% per year in the most
optimistic model simulations presented in Eaton et al., compared
with around 10% over the first year in the IeDEA network of
clinics [31–33].
These inconsistencies between modelling assumptions and
projects and real world situations do not mean that treatment
cannot be used to generate greater reductions in incidence, but
rather that major advances in programme coverage and delivery
will be required to fully exploit the potential prevention benefits of
treatment. These are operational barriers that could be improved
without the development of new scientific prevention technologies,
but which will nevertheless require substantial investment in health
services.
In many models, including several of those in the modelling
comparison [15], several significant simplifying assumptions about
other factors that might influence success were made, because the
exercise was focussed on the impact of a simple and stylized
treatment programme on HIV incidence. In particular, most
models did not explicitly include the relationship between
adherence to ART regimens and degree of viral suppression,
which would affect the therapeutic benefit, the prevention effect,
and the potential for emergence of drug-resistant virus. Drug
resistance is an important issue, especially over the long timescales
considered here, because it effectively weakens the impact of
existing first-line regimens and could cause greater reliance on
second- and third-line treatment regimens, which are currently
more expensive. There are many other considerations that the
modelling comparison by Eaton et al. did not address, such as the
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Figure 1. A framework for understanding the epidemiological impact of HIV treatment. The published results of models [38,53–55] that
have estimated the contribution of different stages of HIV infection to onward transmission are compiled in a median cumulative distribution of
infections generated by one infected person over the course of his/her infection in the absence of treatment (red line). The horizontal axis shows time
from the time of infection to 12 years, which is the mean survival time for those with untreated HIV infection [56]. The vertical axis shows the
cumulative transmission, from 0% (no new infections generated yet) to 100% (all onward transmission completed). (Note that the uncertainty in this
distribution is not indicated.) The shading indicates the approximate CD4 cell count category at each time point [25,26]. Currently, treatment tends to
be initiated well below a CD4 cell count of 200 cells/ml [32], meaning that the contribution of treatment to prevention is minimal because most of the
transmission from that person has already occurred before treatment starts. If increased testing and improved linkages to care enabled individuals to
start treatment at a CD4 cell count very close to 200 cells/ml, this could result in a substantial reduction in HIV incidence, because ,25%–30% of
transmission normally arises from individuals after that point. The prevention impact would be expected to be even greater with initiation close to a
CD4 cell count of 350 cells/ml. If the average number of new infections arising from an infected person in a susceptible population exceeds one
before treatment could be feasibility initiated, then treatment could not eliminate the HIV epidemic. In this framework, the influence of other forms of
prevention will be to change the shape of the graph. For instance, if many men are circumcised or individuals have fewer new sexual partners per
time unit, then new infections arising from an infected person will grow more slowly over time, so that on average one new infection might be
generated only after the point at which a feasible programme could have initiated treatment.
doi:10.1371/journal.pmed.1001259.g001
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use of diagnostic tools that could measure viral load or CD4 cell
count at point of care, which are also the subject of ongoing
research [34–37] but beyond the scope of this collection.
Evidence of Impact from Existing Programmes
Consensus across multiple models can be reassuring, but it is still
possible that all the models could be wrong if, for instance, the
small number of key data sources they rely on are not
representative, or if all the models do not incorporate some
crucial aspects of the system. Another essential check for models is
a comparison of their projections with real data: in this case, the
observed impact of treatment programmes in industrialised
countries that have already achieved good access to treatment
[38]. In this collection, Smith et al. [16] review the data that have
been interpreted as showing that treatment has already had an
impact on reducing incidence, showing apparent consistency
between modelled expectations and reality. However, Smith
et al.[16] advise caution when interpreting the level of evidence
implied, particularly where indirect metrics for ART exposure
(such as community viral load) and proxies for HIV incidence
(such as new diagnoses) are used.
In this collection, Wilson [17] describes the examples of
Australia and France, among other settings, where, despite high
testing rates and coverage of treatment among MSM, HIV
incidence has not decreased. This is in contrast to what models
suggest should have occurred if the assumptions about treatment
as prevention from heterosexual studies are applied to MSM
populations. It will be essential for modellers to learn from the past
by reconciling these and other observations to refine future model
projections.
The Role of Early HIV Infection
One particular issue that may prevent even the most ambitious
treatment programmes from reducing HIV epidemics to very low
levels is the role of early HIV infection in sustaining HIV
transmission. Early HIV infection covers the time shortly after
infection—and usually before HIV diagnosis—when viral con-
centration in the blood spikes and individuals are more infectious
[39]. If a substantial proportion of transmission occurs during
early infection, the impact of treatment programmes will be less
[40] (Figure 1). This could in part explain the apparent lack of
preventive efficacy of ART in epidemics among MSM, as explored
in Australia and elsewhere by Wilson [17] and in other examples
examined by Kumi Smith et al. [16]. However, it is an open
question whether early HIV infection is a dominant factor in
sustaining epidemics in sub-Saharan Africa, and it has been
argued that the contribution of acute infection to sustaining
epidemics is not a primary determinant of the impact of treatment
interventions. In this collection, Cohen et al. [18] debate the size
and significance of this effect, and call for new data to be collected
that may help this to be determined.
Economic Considerations
Ideally, public health policy should be driven by maximising
improvements in the health of populations, rather than by
economic considerations. But the HPTN 052 [11] findings have
come at a difficult time for the public health response to HIV.
After years of rapid growth, funding commitments and disburse-
ments have stabilised or been reduced [41], and only a few
countries in sub-Saharan Africa are currently able to achieve the
high levels of treatment coverage for those eligible recommended
by current international guidelines (Box 2) [1,2]. While the cost of
providing treatment has fallen dramatically in recent years [42],
offering ART to individuals who are not in immediate clinical
need may continue to be significantly more expensive and
complex than other existing methods for reducing HIV transmis-
sion, such as male circumcision [43] and some forms of behaviour
change communication interventions (in particular, voluntary
counselling and testing) [44–46].
To some policy-makers, the slowdown of growth in budgets
available for HIV/AIDS programmes is a sobering constraint and
makes the potential benefits of radical programmes with high
near-term costs irrelevant. Their questions are about the most
cost-effective allocation of incremental changes in resources and
portfolio optimisation in light of the new data about the additional
effect of reducing new infections. To others, the squeeze on
funding is a cue to look for ways to drive large reductions in the
need for resources in the future, which could be generated by an
overhaul of the current epidemic response and an increase in
resources in the short term. New, large investments in controlling
HIV may not be impossible, but there would have to be a strong
case for the return on such an investment.
Estimating Costs
In this collection, Meyer-Rath and Over [19] outline economic
concepts that should guide discussions about the potential for ART
to reduce incidence, and how the programmatic targets identified
by epidemiological modelling could translate into costs. They
argue that the nature of the cost function for ART—that is, the
cost of providing additional patient-years of ART given the
current scale of a programme and practical constraints—has
received insufficient attention in earlier analyses. In particular,
they suggest that the scale and scope of a country’s ART
programme, including clinic size and density, cohort maturity,
patient mix, and health-worker effectiveness, could mean that the
cost of scale-up of ambitious treatment programmes has been
substantially underestimated. However, some projected increases
in cost could be offset if future programmes radically change by
simplifying the delivery of treatment, such as by eliminating
measurement of CD4 counts and/or pre-ART disease monitoring.
In a commentary in this collection on the review by Meyer-Rath
and Over, Ba¨rnighausen et al. [20] consider the dilemma for those
making economic projections for the use of ART as prevention. As
Box 2. Current International Guidelines for
Use of ART
The current World Health Organization international
guidance recommends that HIV-infected patients with
CD4 cell count #350 cells/ml be initiated on ART. In
addition, patients with advanced clinical disease or HIV-
infected people with active tuberculosis should be
immediately initiated on ART, irrespective of CD4 cell
count [58]. In April 2012, new guidance was issued that
HIV-infected individuals with a long-term partner who is
HIV-uninfected could also be considered for ART initiation
[59]. New guidelines will be promulgated by the World
Health Organization in 2013 [60].
However, these guidelines do not necessarily reflect the
care that patients actually receive. National guidelines may
or may not fully reflect the World Health Organization
guidance, and typically, constraints on resources, the
capacity of health systems, and care-seeking behavior
result in individuals being initiated on ART at lower CD4
cell counts than the guidelines recommend.
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ART for prevention represents a significant departure from the
current practice of ART for those in greatest clinical need, it is not
clear how to extrapolate from past experience.
Short-Term versus Long-Term Goals
Another key economic consideration is finding the right level of
spending now to provide the potential for significant benefits in the
long term. The HIV/AIDS epidemic and interventions to stop
HIV and AIDS are inevitably long-wave events [47], so this issue
is particularly important. Treatment programmes spend money
today for returns (in terms of averted infections and deaths, or
reduced costs) years and even decades later. If future costs and
benefits have the same value as current ones, then enormous sums
spent today to eventually avert greater costs and reduce mortality
forever (if incidence is reduced to low levels) would be judged as a
worthwhile expenditure. Whereas, if we accept that, to a decision-
maker, savings that are accrued in the future may be worth less
than those made today, then potential future payoffs may be less
attractive, and investment in programmes for other, more
immediate causes of mortality would be a rational, if not
necessarily an inspiring or ethical, response. Recognition of this
reality for decision-makers requires modellers to vary the relative
value that is assigned to costs and benefits in the future. This is
called discounting. Discounting is just one component of how
decisions are made, and it is important for those contributing to
the debate to be able to couch their arguments in the context of
this fundamental consideration.
Working within Economic Constraints while Increasing
Access
Those making decisions about expanding the provision of ART
for prevention purposes must also plan for the long-term mainte-
nance of such a commitment. Once treatment is initiated, it is
lifelong, and, because relying on treatment to reduce incidence does
not inherently alter the underlying drivers of infectious spread (e.g.,
patterns of sexual contact), future reduction of an ART intervention
effort could lead to a resurgence of the epidemic. Given economic
constraints, the most likely scenario might be for programmes to
increase access to treatment gradually. They could increase access by
expanding eligibility criteria incrementally to include groups who are
most likely to benefit clinically, and whose treatment will most
reduce onward transmission. Several possibilities for doing this have
been raised, including prioritisation according to biological charac-
teristics (e.g., pregnant women, those with active tuberculosis, or
those with high plasma viral loads) or according to behaviours (those
in serodiscordant couples, those attending sexually transmitted
infection clinics, those with many sexual partners, or sex workers).
The epidemiological benefit of providing increased access to
treatment for groups beyond current guidelines will be determined
by the extent to which the criteria being used to prioritise individuals
can reliably identify those who most need treatment or contribute
most to generating new infections.
There are also many other factors that should be considered in
prioritising groups for expanded ART. These include the size of
the group and affordability. The cost to access the group is another
factor. For instance, would it be less costly to reach pregnant
women, who are already in contact with the health system, than
some other groups? The response of a group to treatment also
needs to be considered. For example, would stable couples adhere
to treatment better than others, or would adherence be low if there
is little immediate therapeutic benefit? Ethical considerations,
programme acceptance, and feasibility also need to be taken into
account. For instance, would it be acceptable to provide
serodiscordant couples with preferential access to treatment?
These layers of considerations will not always point to one
particular group as the best option, and local epidemic, economic,
and social conditions will also influence this choice. In addition to
these judgments being unlikely to be clear-cut, they are further
complicated in instances in which human rights and public health
do not necessarily have the same objectives if followed to their
logical ends, for instance, if the best strategy for a population does
not give optimal outcomes for all individuals. In this collection,
Delva et al. [21] review these issues for a wide set of prioritisation
options, and Boily et al. [22] describe how mathematical
modelling can be used to design, conduct, and analyse studies so
that the impact of some of these options can be tested and
compared effectively.
Full accounting of the economic costs and benefits of ART
includes potentially significant macroeconomic benefits (develop-
ment of infrastructure, supply chains, and education, and
productivity gains) and social benefits (reduced orphaning and
increased family stability and employment) derived from spending
on ART programmes, which could also have synergies with, and
spillover benefits for, interventions for other diseases [48]. These
important economic questions are not addressed in this collection
of articles. Nevertheless, incorporating these factors into estimates
of the cost-effectiveness of alternative forms of interventions [49]
or estimates of optimal resource allocation [50] among the
repertoire of antiretroviral-drug-based and non-antiretroviral-
drug-based prevention interventions, even while uncertainties
remain, is an important area of ongoing and future research to
help inform decision-making processes.
Research Agenda: Upcoming Trials
The findings of the HPTN 052 trial [11] demonstrated the
biological efficacy of treatment in reducing infectiousness in
heterosexual individuals who receive the best care and monitoring
that is possible. The durability of the effect over the long term will
be the focus of the next phase of HPTN 052 [51]. The efficacy of
ART in reducing infectiousness from anal sex among MSM is
being investigated in observational studies, such as the Opposites
Attract study in Sydney, Australia (A. Grulich, personal commu-
nication).
Meanwhile, the operational questions will centre on how to
deliver the services that are required for maximising the impact of
treatment on epidemic spread: very high coverage of HIV testing,
frequently repeated HIV testing, strong linkage to care, and high
retention in care. Many studies that are already underway aim to
examine some of these issues [52].
Several large cluster randomized controlled trials that aim to
measure the impact of treatment interventions on HIV incidence
in whole communities will also be initiated shortly. One of these
studies, PopART (HPTN 071) [52], will test the hypothesis that
greatly expanded access to treatment, in combination with access
to other services including safe medical male circumcision, is
feasible and reduces HIV incidence in populations by 60%. The
trials will provide an important and direct test of the predictions
set out by mathematical models, and models will have a key a role
in the design of the studies and the interpretation of findings. In
this collection, Boily et al. [22] describe PopART and other
upcoming trials, and outline the role of modelling before (in
planning and design), during (in monitoring), and after (for
interpretation and extrapolation) trials.
Future Directions: Priorities for Modelling
From consultation with programme leaders, key stakeholders,
community members, and funders at the HIV Modelling Consor-
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tium meeting in 2011, several themes have emerged as priority
issues for further analysis and modelling. First, models need to focus
more specifically on the impact of decisions over short time
horizons, which are of greater relevance when justifying expendi-
ture, as well as on long-term impacts. Second, models should
estimate the impact that programmes may have already had and the
benefits of current policy decisions, rather than only what impact
radically different programmes might have in the distant future.
Third, models should estimate impact in a greater variety of settings,
including concentrated epidemics. Fourth, models should become
better aligned with the experience of real programmes, rather than
using unrealistically optimistic assumptions. And, finally, models
should be utilised to further explore potential negative outcomes of
expanded treatment programmes, such as imperfect adherence,
drug resistance, difficulties in recognising resistance if treatment is
initiated at high CD4 counts, and the potential influence of
compensatory changes in risk behaviours.
At the HIV Modelling Consortium meeting, many called for
modelling to articulate the consequences of reductions in funding,
such as numbers of new treatment initiations decreasing substan-
tially or even current cohorts of treated patients not being
maintained. This modelling would highlight the ethical choices at
the heart of these issues. It was also agreed that models should
incorporate more fully the benefits of earlier treatment initiation,
in terms of a potential, but not certain, additional therapeutic
benefit, reduced incidence of tuberculosis, reduced costs of
prevention of mother-to-child transmission services, reduced cost
of monitoring patients in care and treating opportunistic
infections, and spillover effects such as greater productivity and
reduced numbers of orphans.
There has also been a call to improve communication of
mathematical modelling research to policy-makers, clinicians, and
other researchers so as to better integrate its role into the wider
scientific process and to more clearly articulate the strengths and
weaknesses of particular modelling analyses. In response, Delva
et al. [23] in this collection present some principles of ‘‘best
practice’’ for model presentation and interpretation, which they
hope will become a shared resource for both those who conduct
modelling research and those who use modelling results.
Conclusions
The question of how to best use the tools that have been shown
to reduce HIV transmission will likely dominate the field of HIV
prevention for the foreseeable future. It touches every other aspect
of the response to the worldwide HIV epidemics, from the optimal
allocation of resources in real programmes, to the relative value of
investing in developing additional prevention modalities, to the
global spending that will be required in the future. Epidemiology,
economics, demography, statistics, and mathematical modelling
will be central, and it is hoped that this collection of articles will
provide a solid foundation upon which greater collaborations and
deeper insights will be formed, and will strengthen the support for
evidence-based decision-making, to the benefit of all those whose
lives are threatened by HIV epidemics.
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Key Points
N It has been established that ART for those infected with
HIV can prevent onward transmission of infection, but
biological efficacy alone is not enough to confirm the
impact that ART could have on the HIV epidemic, or to
show how best to use ART to reduce incidence of HIV.
This will be among the most important issues in the field
of HIV prevention for the foreseeable future.
N Epidemiology, economics, demography, statistics, biolo-
gy, and mathematical modelling will be central in
framing key decisions in the optimal use of ART.
N The HIV Modelling Consortium aims to coordinate and
promote research across these disciplines, and facilitate
communication between researchers and policy-makers.
At a collaborative meeting of this consortium in
November 2011, several interlocking themes emerged
that are discussed in this article and covered in more
depth by other articles in this collection.
N Mathematical modelling is used to investigate the
potential impact of treatment on HIV incidence.
However, because of incomplete information on all the
factors that could influence impact, substantial uncer-
tainties will remain. Models should acknowledge those
uncertainties and help prioritise data collection where
this could strengthen model conclusions.
N The current economic constraints on HIV prevention
bring to the fore the role of modelling to help assess the
value and cost-effectiveness of ART. Understanding costs
and integrating costing and epidemiological models will
be key areas of ongoing and future research to help
inform decision-making processes. Models are also being
used to help design and interpret trials that test
hypotheses about the impact of expanded access to
treatment on the spread of HIV in communities.
N We hope that this article and others in the collection will
provide a solid foundation upon which greater collab-
orations between disciplines will be formed, so as to
better integrate the role of modelling into the wider
scientific process and to more clearly articulate the
strengths and weaknesses of particular modelling
analyses. This approach will ultimately strengthen the
support for evidence-based decision-making in HIV
programmes.
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